welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
Antisense Oligonucleotides for the Treatment of Cardiomyopathy in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is an ...
-
A safety and efficacy study of ATL1102 in patients with Duchenne muscular dystrophyCurrent DMD therapies are aimed at incre...
-
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
-
Biomarker for Duchenne Disease (BIODUCHENNE)Development of a new mass spectrometry-b...
-
Summit announces PhaseOut DMD did not meet primary endpointSummit Therapeutics announced today that...
-
A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Duchenne Muscular Dystrophy (DMD) PatientsThis study will be comprised of 2 parts:...
-
DuchenneXchange Clinical Trial Finder LaunchesThe DuchenneXchange Clinical Trial Finde...
-
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
